GHRP-6
Growth hormone secretagogue
One of the earliest growth-hormone-releasing peptides studied. Human work stayed at the level of short hormone-response experiments.
GHRP-2
Also cited in the literature as Pralmorelin
A small peptide that triggers growth hormone release. In Japan it was approved as a diagnostic test rather than a treatment.
Regulatory status: Not licensed as a medicine in the United Kingdom. It holds no MHRA marketing authorisation, has no approved indication, and is not approved for human or animal use.
Hormone & signalling research
Research stage: Approved as a diagnostic agent in Japan; no treatment authorisation
Cells
Animal studies
Human trials
The research pathway — not every compound has reached human trials. Illustrations are simplified, not study results.
What it is
GHRP-2, also called pralmorelin, is a laboratory-made peptide of six amino acids. It acts at the receptor the natural hunger hormone ghrelin uses.
How researchers think it works
Studies found that it activated the ghrelin receptor in the pituitary gland and hypothalamus, prompting a burst of growth hormone release.
What has research seen in people?
Human studies reported clear short-term rises in growth hormone, which is why Japanese regulators approved it as a diagnostic test rather than a treatment.
No trials showed that repeated use changed body composition, strength or health outcomes.
Researchers also recorded effects on appetite and on cortisol, and flagged those as reasons for caution.
Where this material is listed
For laboratory research use only. Not a medicine and not for human or animal use.
Veritide does not sell or supply anything. This links to a third-party UK laboratory supplier; we may earn a commission if you buy through it, at no extra cost to you. Materials are sold for laboratory research use only and are not licensed medicines.
What studies have found
- Published studies in adults and children reported measurable rises in growth hormone after it was given, and Japanese regulators approved it as a diagnostic test for growth hormone deficiency.
- Researchers did not publish trials showing that repeated use improved body composition, strength or health outcomes.
What we still do not know
- The published work measured hormone responses over hours, not long-term effects.
- Effects on appetite and on the hormone cortisol were also reported, and researchers noted these as reasons for caution.
Sources
Related profiles
Retatrutide
Triple incretin receptor agonist
An experimental peptide that acts on three hormone receptors. Researchers studied it in phase 2 trials involving weight and blood sugar.
Mazdutide
Dual GLP-1 / glucagon receptor agonist
An experimental peptide based on a natural gut hormone. Researchers studied it mainly in phase 2 and phase 3 trials in China.